首页 | 本学科首页   官方微博 | 高级检索  
     


Validation of Progression‐Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials
Authors:Xiaofei Wang  Xiaoyi Wang  Lydia Hodgson  Stephen L. George  Daniel J. Sargent  Nate R. Foster  Apar Kishor Ganti  Thomas E. Stinchcombe  Jeffrey Crawford  Robert Kratzke  Alex A. Adjei  Hedy L. Kindler  Everett E. Vokes  Herbert Pang
Affiliation:1. Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA;2. Alliance Statistics and Data Center, Duke University, Durham, North Carolina, USA;3. Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota, USA;4. Department of Internal Medicine, Veterans Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, Nebraska, USA;5. Department of Medicine, Duke University, Durham, North Carolina, USA;6. Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA;7. Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA;8. Department of Medicine, University of Chicago, Chicago, Illinois, USA;9. School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, People's Republic of China
Abstract:
Keywords:Malignant mesothelioma  Surrogate endpoint  Progression‐free survival  Overall survival  Risk factors
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号